A Phase 1b/2, Open-Label, Multi-Center Study of Tivozanib in Combination With Nivolumab in Subjects With Metastatic Renal Cell Carcinoma

Trial Profile

A Phase 1b/2, Open-Label, Multi-Center Study of Tivozanib in Combination With Nivolumab in Subjects With Metastatic Renal Cell Carcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Tivozanib (Primary) ; Nivolumab
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Acronyms TiNivo
  • Sponsors AVEO Oncology
  • Most Recent Events

    • 08 Jun 2017 According to an AVEO Oncology media release, results from phase I portion of this study will be submitted for presentation at an upcoming scientific meeting.
    • 08 Jun 2017 According to an AVEO Oncology media release, Phase 1 dose escalation portion of the trial has been completed and this trial has progressed to the Phase 2 portion.
    • 04 May 2017 According to an AVEO Oncology media release, the company expects to complete the phase I portion of the study in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top